Navigation Links
Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
Date:6/8/2008

HUDSON, N.H., June 9 /PRNewswire/ -- Atrium Medical announced today that it has begun enrollment of the first patients for their CONFIRM 1, First-in-Man (FIM) drug eluting coronary stent clinical trial. Atrium's European FIM clinical trial study is evaluating Atrium's CINATRA(TM) voclosporin coated coronary stent system.

This First-in-Man trial is a prospective, multi-center, single blind, randomized, controlled study using the CINATRA(TM) voclosporin coated coronary stent system, which will be compared to Atrium's CINATRA(TM) bare metal coronary stent (BMS) platform. This first use study of voclosporin on an implantable medical device will enroll 100 patients, and will be conducted at seven hospitals in Belgium with Glenn Van Langenhove, MD, PhD of Middelheim Hospital, Antwerp, as the study's Principal Investigator. The primary endpoint of the trial is to evaluate the safety and performance of the CINATRA(TM) voclosporin coated coronary stent system and the CINATRA(TM) BMS coronary stent system in patients with de novo coronary artery disease. Patient outcomes, in addition to drug coated stent performance, will be assessed by measuring Late Lumen Loss, in-stent and in-segment lumen loss measurements at six months following implantation.

After many years of pre-clinical testing, Atrium is very excited to be able to study the new CINATRA(TM) coronary stent platform with voclosporin, a promising new drug, and the company's all natural O3FA coating technology that merges the desirable safety benefits of a bare metal stent with the clinical advantages of a bio-absorbable Omega 3 fatty acid coating. Use of Atrium's patented Omega 3 coating platform, together with its novel drug compound has created a new class of patient treatment options who require a drug eluting coronary stent. Interventional cardiologists and patients alike have been waiting for a new technology that delivers the effectiveness of a drug eluting stent with a safer, more natural, non-polymer coating platform resulting in a well healed implant shortly after insertion.

About the CINATRA(TM) Voclosporin Drug Eluting Coronary Stent System

The CINATRA(TM) voclosporin coated coronary stent system is an advanced cobalt chromium balloon expandable stent, mounted on a low profile rapid exchange catheter. Atrium's stent and balloon are both coated with Atrium's proprietary Omega 3 fatty acid coating technology, providing a more uniform bio-absorbable delivery vehicle for its anti-inflammatory compound, voclosporin.

About Voclosporin

Voclosporin is a next generation calcineurin inhibitor and was selected for its desired anti-inflammatory properties in the vascular system. Voclosporin is a product of Edmonton-based Isotechnika Inc., licensed exclusively to Atrium Medical in 2005 for use with implantable medical devices.

About Atrium

Atrium's vast expertise in medical device technologies for the treatment of cardiovascular disease, hernia and adhesion prevention has brought a number of breakthrough advances in several diversified healthcare markets including interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, and soft tissue repair. Maintaining a commitment to the latest ISO13485 Quality Standards, state-of-the-art manufacturing and automation, cell biology and biomaterial discovery programs, Atrium continues to excel in those healthcare segments that require more advanced surgical intervention for improvements in patient outcome. For more information, call 800-370-7899 or visit http://www.atriummed.com.


'/>"/>
SOURCE Atrium Medical
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer
2. Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms
3. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
4. Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents
5. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
6. Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting
7. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
8. New Data Show High Frequency of Medical Claims for Gastrointestinal Events by Patients on Antiplatelet Therapy
9. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
10. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
11. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... or "Company") (NASDAQ: UNIS ; ASX: UNS), a developer ... results for the second quarter of fiscal 2016 (three months ended ... Financial Results for the Second Quarter of Fiscal 2016 ... for the second quarter of fiscal 2016 was $4.5 million, compared ... from customers for the second quarter of fiscal 2016 were $17.8 ...
(Date:2/9/2016)... Bermuda, Feb. 9, 2016  Axovant Sciences Ltd. ... on the treatment of dementia, today announced further ... cognitive, behavioral and functional aspects of Lewy body ... in the U.S. Two out of the three ... expected to start later this quarter. In addition, ...
(Date:2/9/2016)... Feb. 9, 2016 Hearing protection devices refer ... energy transmitted to the inner ear. Hearing protection devices ... These devices are recommended for users exposed to noise ... refer to HPD that are inserted in the ear ... designed to provide more natural sound perception with the ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... A new ... schedule rates and Medicare rates for a variety of medical services in Illinois ... Evaluation of the 2015 Fee Schedule Rates in Illinois, are professional medical ...
(Date:2/9/2016)... ... February 09, 2016 , ... Establishment Labs, a global ... David Hung to the company´s Board of Directors. , “We are honored ... and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s ...
(Date:2/9/2016)... County, CA (PRWEB) , ... February 09, 2016 , ... ... on home whitening packages. Teeth whitening is among the most popular cosmetic procedures in ... for their whitening needs. This can put them at risk of teeth whitening-related damage. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Two renowned photographers, Robert ... a photographic adventure on the island, June 14-19, 2016, hosted by Four Seasons Resort ... , After a successful debut in 2015, the Maui Photo Expedition workshop ...
(Date:2/9/2016)... ... February 09, 2016 , ... Shark Finds and Kevin Harrington, and the ... with GRIP-DRY. , GRIP-DRY is a newly patented product that has solved some of the ... the wet and early morning dew or right after a rain shower, might understand the ...
Breaking Medicine News(10 mins):